BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 36581802)

  • 1. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.
    Cai Q; Ding Z; Fu AZ; Patel AA
    BMC Gastroenterol; 2022 Dec; 22(1):545. PubMed ID: 36581802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort.
    Kaplan JL; Liu C; King EC; Bass JA; Patel AS; Tung J; Chen S; Lissoos T; Candela N; Saeed S; Colletti RB;
    J Pediatr Gastroenterol Nutr; 2023 May; 76(5):566-575. PubMed ID: 36804501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn's disease and ulcerative colitis in the United States.
    Gibble TH; Naegeli AN; Grabner M; Isenberg K; Shan M; Teng CC; Curtis JR
    BMC Gastroenterol; 2023 Mar; 23(1):63. PubMed ID: 36894911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
    Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.
    Chen C; Hartzema AG; Xiao H; Wei YJ; Chaudhry N; Ewelukwa O; Glover SC; Zimmermann EM
    Inflamm Bowel Dis; 2019 Jul; 25(8):1417-1427. PubMed ID: 30839057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delay in prior authorization of biologic therapy: Another possible cause of healthcare disparity in IBD patients.
    Rao V; Dharia I; Gibilisco J; Kirelik D; Baumgartner S; Negreira K; Chawla K; Dave J; Kallus S; Belfaqeeh OA; Borum ML
    J Natl Med Assoc; 2024 Feb; 116(1):13-15. PubMed ID: 38036315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.
    Alulis S; Vadstrup K; Olsen J; Jørgensen TR; Qvist N; Munkholm P; Borsi A
    BMC Health Serv Res; 2021 Aug; 21(1):836. PubMed ID: 34407821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
    [No Abstract]   [Full Text] [Related]  

  • 11. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.
    Anisdahl K; Svatun Lirhus S; Medhus AW; Moum B; Melberg HO; Høivik ML
    Scand J Gastroenterol; 2021 Oct; 56(10):1163-1168. PubMed ID: 34320885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study.
    Khoudari G; Mansoor E; Click B; Alkhayyat M; Saleh MA; Sinh P; Katz J; Cooper GS; Regueiro M
    Clin Gastroenterol Hepatol; 2022 May; 20(5):e974-e983. PubMed ID: 33065311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocol.
    Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
    BMJ Open; 2023 Oct; 13(10):e073071. PubMed ID: 37788929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States.
    Siegel CA; Yang F; Eslava S; Cai Z
    Clin Transl Gastroenterol; 2020 Feb; 11(2):e00128. PubMed ID: 32463619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.
    Shehab M; Alrashed F; Alkazemi A; Lakatos PL; Bessissow T
    Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):469-477. PubMed ID: 36961082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
    AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
    J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
    Krugliak Cleveland N; Ghosh S; Chastek B; Bancroft T; Candela N; Fan T; Umashankar K; Rubin DT
    Inflamm Bowel Dis; 2023 Oct; ():. PubMed ID: 37921344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in surgery rates among hospitalized patients with inflammatory bowel disease in Japan from 2015 to 2019: A nationwide administrative database analysis.
    Yoshida S; Imai S; Fushimi K
    J Gastroenterol Hepatol; 2024 Feb; 39(2):272-279. PubMed ID: 37961024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in systemic steroid use and surgery rate in patients with inflammatory bowel disease: a Japanese real-world database analysis.
    Hirayama D; Hyodo S; Morita K; Nakase H
    J Gastroenterol; 2024 May; 59(5):389-401. PubMed ID: 38492011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
    Brady JE; Stott-Miller M; Mu G; Perera S
    Clin Ther; 2018 Sep; 40(9):1509-1521.e5. PubMed ID: 30126706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.